Biomarkers for detection of clinically significant prostate cancer : contemporary clinical data and future directions
2021 Translational Andrology and Urology. All rights reserved..
Use of serum prostate-specific antigen (PSA) testing for early detection of prostate cancer appears to reduce cancer-specific mortality. Due to the limited specificity of PSA for clinically significant [Grade Group (GG) ≥2] cancer, however, screening carries substantial risks, including frequent unnecessary prostate biopsies and overdetection of non-aggressive cancers. To that end, serum and urine biomarkers with improved specificity for GG ≥2 cancer have been proposed for clinical use following PSA. In the current article, we present clinical validation data for five such biomarkers: PHI, 4Kscore, SelectMDx, ExoDx, and MPS. For all studies, we specify the study population (overall biopsy referral vs. pre-specified PSA ranges), previous biopsy status (biopsy-naïve vs. previous negative biopsy), and the proportion of subjects diagnosed with GG ≥2 cancer. Outcomes include test performance characteristics: sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV). Published data were used to compute the number of unnecessary biopsies avoided and number of GG ≥2 cancers missed if the biomarker had been used clinically to select for prostate biopsy. The evidence review is preceded by a primer on these and other clinically-relevant summary statistics.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Translational andrology and urology - 10(2021), 7 vom: 25. Juli, Seite 3091-3103 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Eyrich, Nicholas W [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biopsy |
|---|
| Anmerkungen: |
Date Revised 10.09.2022 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.21037/tau-20-1151 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32973640X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32973640X | ||
| 003 | DE-627 | ||
| 005 | 20231225205751.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21037/tau-20-1151 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1099.xml |
| 035 | |a (DE-627)NLM32973640X | ||
| 035 | |a (NLM)34430413 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Eyrich, Nicholas W |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Biomarkers for detection of clinically significant prostate cancer |b contemporary clinical data and future directions |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.09.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a 2021 Translational Andrology and Urology. All rights reserved. | ||
| 520 | |a Use of serum prostate-specific antigen (PSA) testing for early detection of prostate cancer appears to reduce cancer-specific mortality. Due to the limited specificity of PSA for clinically significant [Grade Group (GG) ≥2] cancer, however, screening carries substantial risks, including frequent unnecessary prostate biopsies and overdetection of non-aggressive cancers. To that end, serum and urine biomarkers with improved specificity for GG ≥2 cancer have been proposed for clinical use following PSA. In the current article, we present clinical validation data for five such biomarkers: PHI, 4Kscore, SelectMDx, ExoDx, and MPS. For all studies, we specify the study population (overall biopsy referral vs. pre-specified PSA ranges), previous biopsy status (biopsy-naïve vs. previous negative biopsy), and the proportion of subjects diagnosed with GG ≥2 cancer. Outcomes include test performance characteristics: sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV). Published data were used to compute the number of unnecessary biopsies avoided and number of GG ≥2 cancers missed if the biomarker had been used clinically to select for prostate biopsy. The evidence review is preceded by a primer on these and other clinically-relevant summary statistics | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Prostate-specific antigen (PSA) | |
| 650 | 4 | |a biopsy | |
| 650 | 4 | |a neoplasm grading biomarkers | |
| 650 | 4 | |a prostatic neoplasms | |
| 650 | 4 | |a tumor | |
| 700 | 1 | |a Morgan, Todd M |e verfasserin |4 aut | |
| 700 | 1 | |a Tosoian, Jeffrey J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Translational andrology and urology |d 2012 |g 10(2021), 7 vom: 25. Juli, Seite 3091-3103 |w (DE-627)NLM219254222 |x 2223-4691 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2021 |g number:7 |g day:25 |g month:07 |g pages:3091-3103 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21037/tau-20-1151 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2021 |e 7 |b 25 |c 07 |h 3091-3103 | ||